Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Literature DB >> 32055486

Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Bilal A Siddiqui¹, Miao Zhang², Louis L Pisters³, Shi-Ming Tu⁴.

Abstract

Testicular germ cell tumors are the most common solid tumors in young men. These cancers represent a success story of modern medicine in our ability to cure young patients and offer decades of life, with a 5-year survival rate of approximately 95%. This review outlines the staging and risk classification of testicular cancers, and reviews the current state of knowledge and standard of care for the systemic treatment of testicular germ cell tumors with chemotherapy, focusing on the relevant clinical data supporting each treatment regimen. This review also briefly highlights current areas of active investigation, notably in the relapsed and refractory setting, including ongoing clinical trials. 2020 Translational Andrology and Urology. All rights reserved.

Entities: Disease Species

Keywords: Neoplasms; germ cell and embryonal; non-seminomatous germ cell tumor; seminoma; testicular germ cell tumor

Year: 2020 PMID： 32055486 PMCID： PMC6995840 DOI： 10.21037/tau.2019.09.11

Source DB: PubMed Journal: Transl Androl Urol ISSN： 2223-4683

80 in total

Review 1. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.

Authors: G Cohn-Cedermark; O Stahl; T Tandstad
Journal: Andrology Date: 2014-10-01 Impact factor: 3.842

2. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.

Authors: M Behnia; R Foster; L H Einhorn; J Donohue; C R Nichols
Journal: Eur J Cancer Date: 2000-03 Impact factor: 9.162

Review 3. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype.

Authors: Mark H Greene; Christian P Kratz; Phuong L Mai; Christine Mueller; June A Peters; Gennady Bratslavsky; Alex Ling; Peter M Choyke; Ahalya Premkumar; Janet Bracci; Rissah J Watkins; Mary Lou McMaster; Larissa A Korde
Journal: Endocr Relat Cancer Date: 2010-03-08 Impact factor: 5.678

4. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up.

Authors: Graham M Mead; Sophie D Fossa; R Timothy D Oliver; Johnathan K Joffe; Robert A Huddart; J Trevor Roberts; Philip Pollock; Rhian Gabe; Sally P Stenning
Journal: J Natl Cancer Inst Date: 2011-01-06 Impact factor: 13.506

5. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

Authors: S Culine; P Kerbrat; A Kramar; C Théodore; C Chevreau; L Geoffrois; N B Bui; J Pény; A Caty; R Delva; P Biron; K Fizazi; J Bouzy; J P Droz
Journal: Ann Oncol Date: 2007-03-09 Impact factor: 32.976

6. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

Authors: Karim Fizazi; Rémi Delva; Armelle Caty; Christine Chevreau; Pierre Kerbrat; Frederic Rolland; Frank Priou; Lionnel Geoffrois; Olivier Rixe; Philippe Beuzeboc; Jean-Pierre Malhaire; Stephane Culine; Marie-Stephanie Aubelle; Agnes Laplanche
Journal: Eur Urol Date: 2013-09-13 Impact factor: 20.096

7. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors: Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544

Review 8. Surgical management of low-stage nonseminomatous germ cell testicular cancer.

Authors: Andrew J Stephenson; Eric A Klein
Journal: BJU Int Date: 2009-11 Impact factor: 5.588

9. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Authors: Torgrim Tandstad; Olav Dahl; Gabriella Cohn-Cedermark; Eva Cavallin-Stahl; Ulrika Stierner; Arne Solberg; Carl Langberg; Roy M Bremnes; Anna Laurell; Hans Wijkstrøm; Olbjørn Klepp
Journal: J Clin Oncol Date: 2009-03-23 Impact factor: 44.544

Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment.

Review 1. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience.

2. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.

Review 3. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype.

4. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up.

5. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

6. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

Review 8. Surgical management of low-stage nonseminomatous germ cell testicular cancer.

9. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

10. Testicular seminoma clinical stage 1: treatment outcome on a routine care level.

1. Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center.

2. LAPTM5 Plays a Key Role in the Diagnosis and Prognosis of Testicular Germ Cell Tumors.

Review 3. Epigenetics and Testicular Cancer: Bridging the Gap Between Fundamental Biology and Patient Care.